Cilostazol exerts antiplatelet and anti-inflammatory effects through AMPK activation and NF-kB inhibition on...

Area of Science:

• Biochemistry
• Pharmacology
• Cardiovascular Research

Background:

• Atherosclerosis is a chronic inflammatory disease driven by lipid accumulation and platelet activation.
• Understanding the molecular mechanisms underlying early atherosclerosis is crucial for developing effective interventions.

Purpose of the Study:

• To investigate the molecular mechanisms by which cilostazol, a phosphodiesterase 3 inhibitor (PDE3-inhibitor), modulates platelet signaling pathways to prevent early atherosclerosis.
• To evaluate the effects of cilostazol on lipid profiles, oxidative stress, and inflammatory markers in a rat model of hypercholesterolemia.

Main Methods:

• Male Wistar rats were fed a high-cholesterol diet (HCD) for 45 days, with cilostazol administered orally during the last 15 days.
• Assessed platelet aggregation, lipid profile, lipid peroxidation, and serum cytokine levels.
• Utilized Western blot analysis to examine the expression and activation of key proteins involved in platelet signaling, including P-selectin, CD40L, PKC-α, IkB-α, iNOS, AMPK, NF-κB, and eNOS.

Main Results:

• Cilostazol significantly reduced total cholesterol, triglycerides, LDL-cholesterol (cLDL), VLDL-cholesterol (cVLDL), and malondialdehyde levels compared to the HCD group.
• Cilostazol demonstrated antiplatelet properties, evidenced by decreased platelet aggregation and reduced expression of inflammatory markers like P-selectin and CD40L.
• Molecular analysis revealed that cilostazol's beneficial effects were associated with activation of AMP-activated protein kinase (AMPK), inhibition of nuclear factor-kappa B (NF-κB), and activation of endothelial nitric oxide synthase (eNOS).

Conclusions:

• Cilostazol exhibits significant anti-atherosclerotic effects in a hypercholesterolemic rat model.
• These effects are mediated by a combination of lipid-lowering, anti-oxidative, and anti-inflammatory actions.
• The observed benefits are linked to the modulation of key platelet signaling pathways, including AMPK activation, NF-κB inhibition, and eNOS activation, highlighting cilostazol's therapeutic potential in preventing early atherosclerosis.